> Details

Conti, Matteo; Bolzacchini, Elena; Luchena, Giovanna; Bertu’, Lorenza; Tagliabue, Paola; Aglione, Stefania; Ardizzoia, Antonio; Arnoffi, Jessica; Guida, Francesco Maria; Bertolini, Alessandro; Pastorini, Alessandro; Duro, Maria; Bettega, Donato; Roda’, Giovambattista; Artale, Salvatore; Squizzato, Alessandro; Giordano, Monica

Tas-102 for Refractory Metastatic Colorectal Cancer: A Multicenter Retrospective Cohort Study

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Tas-102 for Refractory Metastatic Colorectal Cancer: A Multicenter Retrospective Cohort Study
  • Contributor: Conti, Matteo; Bolzacchini, Elena; Luchena, Giovanna; Bertu’, Lorenza; Tagliabue, Paola; Aglione, Stefania; Ardizzoia, Antonio; Arnoffi, Jessica; Guida, Francesco Maria; Bertolini, Alessandro; Pastorini, Alessandro; Duro, Maria; Bettega, Donato; Roda’, Giovambattista; Artale, Salvatore; Squizzato, Alessandro; Giordano, Monica
  • Published: MDPI AG, 2023
  • Published in: Cancers, 15 (2023) 13, Seite 3465
  • Language: English
  • DOI: 10.3390/cancers15133465
  • ISSN: 2072-6694
  • Origination:
  • Footnote:
  • Description: Trifluridine/tipiracil (TAS-102) is an oral chemotherapy approved for the treatment of metastatic colorectal cancer. The efficacy and tolerability of TAS-102 were shown in phase II-III clinical trials and in several real-life studies. The elderly and other special subgroups are underrepresented in published literature. We conducted a retrospective multicenter study to assess the effectiveness and safety of TAS-102 in consecutive patients with pretreated mCRC. In particular, we estimated the effectiveness and safety of TAS-102 in elderly patients (aged ≥70, ≥75 and ≥80 years) and in special subgroups, e.g., patients with concomitant heart disease. One hundred and sixty patients were enrolled. In particular, 71 patients (44%) were 70 years of age or older, 50 (31%) were 75 years of age or older, and 23 (14%) were 80 years of age or older. 19 patients (12%) had a concomitant chronic heart disease, three (2%) patients were HIV positive, and one (<1%) patient had a DPYD gene polymorphism. In 115 (72%) cases TAS-102 was administered as a third-line treatment. The median overall survival (OS) in the overall population was 8 months (95% confidence interval [CI], 6–9), while the median progression-free survival (PFS) was 3 months (95% CI, 3–4). No significant age-related reduction in effectiveness was observed in the subpopulations of elderly patients included. The toxicity profile was acceptable in both the whole and subgroups’ population. Our study confirms the effectiveness and safety of TAS-102 in patients with pretreated mCRC, suggesting a similar risk-benefit profile in the elderly.
  • Access State: Open Access